CDK4 and cancer: A drug screening performed in pancreatic cancer cell lines, comprising more than 300 anti-cancer compounds combined with Palbociclib, revealed that CDK4/6 inhibition protected cancer cells from chemotherapeutic drugs that targeted mitotic machinery and, thus, require an active cell cycle progression for their action (82).